TY - JOUR
T1 - HIV and risk of cardiovascular disease in sub-Saharan Africa
T2 - Rationale and design of the Ndlovu Cohort Study
AU - Vos, Alinda
AU - Tempelman, Hugo
AU - Devillé, Walter
AU - Barth, Roos
AU - Wensing, Annemarie
AU - Kretzschmar, Mirjam
AU - Klipstein-Grobusch, Kerstin
AU - Hoepelman, Andy
AU - Tesselaar, Kiki
AU - Aitken, Sue
AU - Madzivhandila, Mashudu
AU - Uiterwaal, Cuno
AU - Venter, Francois
AU - Coutinho, Roel
AU - Grobbee, Diederick E
N1 - Publisher Copyright:
© European Society of Cardiology.
PY - 2017/7
Y1 - 2017/7
N2 - Background The largest proportion of people living with HIV resides in sub-Saharan Africa (SSA). Evidence from developed countries suggests that HIV infection increases the relative risk of cardiovascular disease (CVD) by up to 50%. Differences in lifestyle, gender distribution, routes of HIV transmission and HIV subtype preclude generalisation of data from Western countries to the SSA situation. The Ndlovu Cohort Study aims to provide insight into the burden of cardiovascular risk factors and disease, the mechanisms driving CVD risk and the contribution of HIV infection and its treatment to the development of CVD in a rural area of SSA. Design The Ndlovu Cohort Study is a prospective study in the Moutse area, Limpopo Province, South Africa. Methods A total of 1000 HIV-positive and 1000 HIV-negative participants aged 18 years and older with a male to female ratio of 1:1 will be recruited. Measurements of CVD risk factors and HIV-related characteristics will be performed at baseline, and participants will be followed-up over time at 6-month intervals. The burden of CVD will be assessed with repeated carotid intima-media thickness and pulse wave velocity measurements, as well as by recording clinical cardiovascular events that occur during the follow-up period. Conclusion This project will contribute to the understanding of the epidemiology and pathogenesis of CVD in the context of HIV infection in a rural area of SSA. The ultimate goal is to improve cardiovascular risk prediction and to indicate preventive approaches in the HIV-infected population and, potentially, for non-infected high-risk populations in a low-resource setting.
AB - Background The largest proportion of people living with HIV resides in sub-Saharan Africa (SSA). Evidence from developed countries suggests that HIV infection increases the relative risk of cardiovascular disease (CVD) by up to 50%. Differences in lifestyle, gender distribution, routes of HIV transmission and HIV subtype preclude generalisation of data from Western countries to the SSA situation. The Ndlovu Cohort Study aims to provide insight into the burden of cardiovascular risk factors and disease, the mechanisms driving CVD risk and the contribution of HIV infection and its treatment to the development of CVD in a rural area of SSA. Design The Ndlovu Cohort Study is a prospective study in the Moutse area, Limpopo Province, South Africa. Methods A total of 1000 HIV-positive and 1000 HIV-negative participants aged 18 years and older with a male to female ratio of 1:1 will be recruited. Measurements of CVD risk factors and HIV-related characteristics will be performed at baseline, and participants will be followed-up over time at 6-month intervals. The burden of CVD will be assessed with repeated carotid intima-media thickness and pulse wave velocity measurements, as well as by recording clinical cardiovascular events that occur during the follow-up period. Conclusion This project will contribute to the understanding of the epidemiology and pathogenesis of CVD in the context of HIV infection in a rural area of SSA. The ultimate goal is to improve cardiovascular risk prediction and to indicate preventive approaches in the HIV-infected population and, potentially, for non-infected high-risk populations in a low-resource setting.
KW - Human immunodeficiency virus
KW - cardiovascular disease
KW - cardiovascular risk factors
KW - carotid intima–media thickness measurement
KW - cohort study
KW - pulse wave velocity
U2 - 10.1177/2047487317702039
DO - 10.1177/2047487317702039
M3 - Article
C2 - 28379043
SN - 2047-4873
VL - 24
SP - 1043
EP - 1050
JO - European Journal of Preventive Cardiology
JF - European Journal of Preventive Cardiology
IS - 10
ER -